SCHEMBL7239764

SCHEMBL7239764

CCc1cc(C(=O)O)n(-c2cccc(C#N)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.46
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
GRN P28799 1/20 0.42
SORT1 Q99523 1/20 0.42
NSD2 O96028 1/20 0.40
KLKB1 P03952 1/20 0.40
F10 P00742 1/20 0.40
DRD2 P14416 2/20 0.40
GRIA2 P42262 1/20 0.39
GRIA4 P48058 1/20 0.39
GRM5 P41594 1/20 0.39
F11 P03951 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CCR2 P41597 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831066 0.88 NOTUM (0.43) NOTUMALDH1A1GAAGRNSORT1
SCHEMBL23403904 0.84 KLKB1 (0.46) NOTUMALDH1A1GAAGRNSORT1
SCHEMBL1680141 0.83 F10 (0.53) NOTUMALDH1A1GAAGRNSORT1
SCHEMBL15869371 0.82 ALDH1A1 (0.60) ALDH1A1GAAGRNSORT1KLKB1
Hydrochloric Acid SCHEMBL3830146 0.82 F10 (0.52) NOTUMALDH1A1GAAGRNSORT1
SCHEMBL2926051 0.81 ALDH1A1 (0.68) NOTUMALDH1A1GAAGRNSORT1
SCHEMBL3834923 0.80 KMT2A (0.49) NOTUMALDH1A1GAATP53
SCHEMBL2906729 0.80 GRN (0.69) NOTUMALDH1A1GAAGRNSORT1
SCHEMBL2927010 0.79 NSD2 (0.44) NOTUMALDH1A1GAANSD2DRD2
SCHEMBL17064546 0.79 SCN9A (0.47) NOTUMALDH1A1GAAKLKB1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10329260-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2019-06-25 US disclosed
US-6548512-B1 Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-15 US disclosed
EP-0946508-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-10-06 EP disclosed
WO-1998028269-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329260-B2 Human plasma kallikrein inhibitors KLKB1, KLK1, KLK5 NOTUM 493/4885ALDH1A1 1065/4885GAA 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.